Efficient pathogen detection is essential for the successful treatment and prevention of infectious 9 disease; however, current methods are often too time intensive to be clinically relevant in cases 10 requiring immediate intervention. We have developed a Surface Programmable Activation 11 Receptor (SPAR) diagnostic platform comprised of universal biosensor cells engineered for use 12 in combination with custom or commercial antibodies to achieve rapid and sensitive pathogen 13 detection. SPAR cells are stably transfected Jurkat T cells designed to constitutively express a 14 modified T cell mouse FcγRI receptor on the cell surface and a high level of the luminescent 15 reporter protein aequorin in the cytoplasm. The modified mFcγRI-CD3ζ receptor protein binds 16 with high affinity to the Fc region of any full-length mouse IgG2a and some IgG2 antibodies: 17 this allows customized target detection via the selection of specific antibodies. T-cell receptor 18 aggregation in response to target antigen binding results in signal transduction which, when 19 amplified via the endogenous T cell signal cascade, triggers the rapid intracellular release of 20 calcium. Increased Ca 2+ concentrations activate the expressed reporter protein aequorin resulting 21 in the immediate emission of detectable light. Testing demonstrates the accurate and specific 22 2
90% prior to the addition of selection antibiotics. Blasticidin was then added to a final 140 concentration of 3 μg/mL to select for cells with chromosomal integration of mFcγRI-CD3ζ. 141 Cells were cultured in Complete RPMI 1640 medium supplemented with 3 μg/mL blasticidin for 142 2-3 weeks to allow selection to occur and cell viability to recover to at least 90% before 143 verification tests were performed. was generated through single cell sorting from the top 10% of mFcγRI-CD3ζ expressing SPAR 158 mFcγRI-CD3ζ mixed population cells. SPAR Jurkat P5G7 cells were expanded and analyzed for 159 mFcγRI-CD3ζ receptor expression using the method described above. Generation of serotype-specific mouse monoclonal antibody against E. coli O111 LPS. 188 Serotype-specific mouse monoclonal antibody against E. coli O111 LPS was generated by 189 Precision Antibody (Columbia, MD) using antigen prepared and supplied by this laboratory. microcentrifuge tube to a final antibody concentration of 9.8 µg/mL at room temperature for 10 210 minutes. To begin the assay, the antibody-coated SPAR cells were added to an overnight culture 211 of E. coli O111 that was serially diluted to a concentration of 10,000 CFUs/mL (confirmed by 212 plating and counting) and was already placed in the luminometer. The light signal was recorded 213 immediately and continuously for 4 minutes. Additional controls included 1) testing without 214 antibody, wherein 180 µL of the resuspended biosensor cells were added directly to the serially 215 diluted E. coli O111 in a 1.7 mL microcentrifuge tube placed in the luminometer, and 2) testing 216 without bacteria, in which 180 µL of the biosensors were added directly to 1.6 µL of 1.25 217 mg/mL mouse anti-E. coli O111 LPS IgG in a 1.7 mL microcentrifuge tube in the luminometer.
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All tests were performed in triplicate. The cytoplasmic aequorin luminescent reporter system (Figure 1, upper When expressed, the modified TCR complex (Figure 2 B) 
